Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

R. Yazbeck*, S.E. Jaenisch, C.A. Abbott
College of Medicine and Public Health & Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia
College of Science and Engineering, Flinders University, Adelaide, Australia

ARTICLE INFO
Keywords:
Dipeptidyl peptidase
DPP4 inhibitor
Sitagliptin
Immunity
Innate immunity
Neutrophil
Macrophage

ABSTRACT
Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.

1. Introduction
Dipeptidyl peptidase (DPP)-4 is a transmembrane serine protease that has emerged as a potent pharmacological target for the treatment of Type-2 diabetes. DPP4 is part of the S9B sub-family of serine proteases that also includes the structurally homologous: fibroblast activation protein (FAP), DPP8 and DPP9. These proteases all have unique enzyme activity, cleaving N-terminal dipeptides from regulatory peptides with a proline or alanine residue in the penultimate position (i.e. X-Pro or X-Ala) [1,2]. DPP4 protein expression and enzyme activity has been localised to the apical surface of endothelial, epithelial cells and activated lymphocytes, with abundant expression in the lungs, kidney, liver, and small intestine [3]. An enzymatically active, soluble form of DPP4 has also been identified and is thought to result from the enzymatic shedding of membrane bound DPP4 from various cell types, including adipocytes, smooth muscle cells, and specialised T-lymphocytes [4,5].

Sitagliptin (Januvia, Merck) was the first, highly selective dipeptidyl peptidase (DPP)-4 inhibitor to gain FDA approval as an orally available, small molecule inhibitor with clinical indication for type-2 diabetes [6]. This class of inhibitors acts by blocking DPP4 mediated cleavage of the incretin hormone, glucagon-like peptide-1 (GLP-1) and GIP, prolonging its insulinotropic activity [2,7]. Since then, many DPP4 inhibitors, broadly classed as the ‘gliptins’ and each with discrete structural differences and binding mechanisms, have entered the pharmaceutical market (Table 1). Whilst the clinical efficacy of DPP4 inhibitors have been reported in several large scale clinical studies, and meta-analyses [8,9], emerging evidence continues to suggest complex immunoregulatory roles for DPPs with potential implications for long-term use (i.e. daily ingestion for more than 3 months) of DPP4 inhibitors [10].

Innate and adaptive immunity are no longer considered distinct entities, with fluidity between the two responses maintaining a state of immune homeostasis [11]. The role of DPP4 in adaptive immune responses has been previously described [12]; however, an understanding of the importance of DPP4 in innate immunity is emerging. Ohnuma et al has described links between DPP4, the innate and adaptive immune system, reporting that interactions between DPP4 on T-cells and caveolin-1 on antigen presenting cells lead to costimulatory signals that result in the proliferation of antigen specific T cells [13]. Recent, large cohort studies have also suggested that DPP4 inhibitor use could be associated with an increased risk for pancreatitis in a small sub-group of patients [14,15].

Some of the earliest published studies used DPP4 inhibitors to investigate whether DPP4 enzyme activity modulated T-cell activity and function [16,17]. Inhibition of DPP4 in mitogen stimulated T-cells from human blood suppressed IL-2 and IFN-γ production, while also reducing T-cell proliferation [17], with similar findings also reported in antigen stimulated T-cell lines [16]. These initial findings suggested that the DPP4 inhibitors were blocking the enzymatic activity of DPP4 against immunoregulatory substrates such as chemokines [18]. However, early iterations of DPP4 inhibitors were non-selective, and off-target effects via binding of DPP8 or DPP9 could not be excluded [19].

We have previously reported on DPP4 inhibitors as potential...
Table 1
Selective DPP4 inhibitors approved for the clinical management of type-2 diabetes.

| Inhibitor  | Company/Company Approving body and Year | Chemical Structures | IC50 (nmol/L) | Reference |
|------------|-----------------------------------------|---------------------|--------------|-----------|
|            |                                         |                     | DPP4 | DPP8 | DPP9 |                |
|Sitagliptin (Januvia) | Merck & Company FDA/US 2006 | ![Chemical Structure](image01.png) | 18 | 4.8x10^4 | >1.0x10^5 | [20] |
|Vildagliptin (Galvus) | Novartis EU 2007 | ![Chemical Structure](image02.png) | 100 | 9x10^3 | [21] |
|Saxagliptin (Onglyza) | Bristol-Myers Squibb & Astra Zeneca FDA/US 2009 | ![Chemical Structure](image03.png) | 4 | – | – | [22] |
|Linagliptin (Tradjenta) | Eli Lilly & Company and Boehringer Ingelheim FDA/US 2011 | ![Chemical Structure](image04.png) | 1 | 4x10^4 | >1x10^4 | [23] |
|Gemigliptin | LG Life Sciences Korea 2012 | ![Chemical Structure](image05.png) | 10 | 2.7x10^5 | 2.3x10^4 | [24] |
|Anagliptin (Suiny) | Sanwa Kagaku Japan 2012 | ![Chemical Structure](image06.png) | 3.8–5.3 | 68 | 60 | [25] |

(continued on next page)
| Inhibitor    | Company                  | Approving body and Year | Chemical Structures | IC50 (nmol/L) | Reference |
|-------------|--------------------------|--------------------------|---------------------|--------------|-----------|
| Teneligliptin (Tenelia) | Mitsubishi Tanabe Pharma | Japan 2012               | ![Chemical Structure](image1) | 0.37 260 540 | [26]      |
| Alogliptin (Nesina)   | Takeda                   | FDA/US 2013              | ![Chemical Structure](image2) | 7 >1x10^5 >1x10^5 | [27]      |
| Imigliptin           | Xuanzhu Pharma Co Ltd    | China 2014               | ![Chemical Structure](image3) | 9 >1x10^5 >1x10^5 | [28]      |
| Trelagliptin         | Japan                    | 2015                     | ![Chemical Structure](image4) | 1.3 – –      | [29]      |
| Omarigliptin         | Merck & Co               | Japan 2015               | ![Chemical Structure](image5) | 1.6 >6.7x10^4 >6.7x10^4 | [30]      |

(continued on next page)
DPP4 inhibitors: Clinical safety

The safety and efficacy of the DPP4 inhibitors has been reported in several meta-analyses. A systematic review of 29 studies published between 2004 and 2007 by Amori et al. found that Sitagliptin and Vildagliptin were highly effective for blood sugar management and were more likely to reduce glycosylated haemoglobin compared to placebo [8]. The risk of adverse reactions, including infections and gastrointestinal complications such as nausea, diarrhoea and vomiting, was relatively low overall in patients receiving DPP4 inhibitor therapy [8]. Urinary tract infections were the most common adverse event for all DPP4 inhibitors compared with non-incretin based hypoglycaemic agents [8]. Subsequent studies by Williams-Herman et al. and Karagiannis et al. have reported no significant differences in the rates of infections, including upper respiratory tract and urinary tract infections, between patients treated with DPP4 inhibitors compared to placebo [9,32] or conventional diabetic therapies [9].

Although rare, acute pancreatitis is the most reported serious adverse event associated with DPP4 inhibitor use. A comparison of adverse event reports lodged to the FDA over a 9 year period found that Sitagliptin use increased the odds ratio for pancreatitis 6-fold compared to other therapies [33]. In contrast, a large retrospective study that analysed pharmaceutical claims data from 786,656 patients found that the incidence of pancreatitis was unchanged in patients receiving Sitagliptin compared to other type-2 diabetes medications [34]. Recent meta-analyses of the DPP4 inhibitors Sitagliptin, Alogliptin, Linagliptin, Saxagliptin and Vildagliptin found a marginally higher risk of developing acute pancreatitis with DPP4 inhibitor use [14,15]. The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) trial also reported a small but increased risk of pancreatitis in patients taking Linagliptin [35]. However, the Cardiovascular Outcome Study of Linagliptin vs Glimepiride in Type 2 Diabetes (CAROLINA) study found no increased risk of pancreatitis in the Linagliptin group [36]. Acute pancreatitis is characterised by a TNF-α, IL-1, IL-6 and IL-8 pro-inflammatory immune response [37], with neutrophils and macrophages driving this response [38]. Whilst the exact mechanisms associated with DPP4 inhibitor use and pancreatitis are still unknown, their effects on innate immunity could reveal novel insights into their pharmacological actions.

3. Dipeptidyl peptidases and innate immunity

Emerging evidence suggests that DPP4 inhibitors could modulate innate immune responses, with potential clinical implications. Whilst the role of DPP4 in adaptive immunity has been previously described, it is increasingly apparent that DPP4 inhibitors can modify specific components of innate immunity, including vascular endothelial cell, neutrophil and monocyte/macrophage mediated responses (Fig. 1). The diverse range of DPP4 substrates, with overlapping roles in innate immunity, suggests multiple pathways that could be impacted by DPP4 inhibition (Table 2).

Table 1 (continued)

| Inhibitor      | Company       | Approving body and Year | Chemical Structures | IC50 (nmol/L) | Reference |
|----------------|---------------|--------------------------|---------------------|---------------|-----------|
|                |               |                          |                     | DPP4 | DPP8 | DPP9 |             |           |
| Evogliptin     | Korea 2015    |                          | ![Chemical Structures](attachment) | 0.9 | – | – | [31] |
existing coronary artery disease, endothelial function was significantly improved after six months of treatment with Sitagliptin (50 mg/day) compared to conventional therapy [42]. Rizzo et al found a reduction in circulating pro-inflammatory cytokines and the oxidative stress marker, nitrotyrosine in a perspective, randomized open label study of Type-2 diabetics taking either Sitagliptin or Vildagliptin [43]. The authors reported superior effects with Vildagliptin, suggesting glycaemic control and inhibitor kinetics were responsible for the immunomodulatory effects. However, the authors did not exclude the possibility of a non-glycaemic effect of DPP4 inhibitors in regulating endothelial cell mediated innate immunity [43].

Glucose independent effects of DPP4 inhibitors have been described in pre-clinical studies as modifying endothelial mediated immunity. Kroller-Schon et al found that vascular function was maintained in linagliptin treated rats with lipopolysaccharide (LPS)-induced septic shock compared to control groups [44]. The authors also reported that Linagliptin treatment attenuated vascular oxidative stress markers. Linagliptin also reduced expression of the inflammatory markers vascular cell adhesion molecule (VCAM)-1, cyclooxygenase-2, nitric oxide synthase and myeloperoxidase [44]. Using the DPP4 inhibitor, Gemigliptin, Hwang et al also demonstrated decreased expression of VCAM-1 and the neutrophil binding protein, E-selectin, in LPS stimulated human umbilical vein endothelial cells (HUVEC) cells in vitro [45]. Gemigliptin also blocked LPS-mediated activation of pro-inflammatory transcription factors JNK and NF-κB via an Akt/AMP-activated protein kinase dependent pathway in vitro [46]. Monocyte (THP-1 cell) adhesion to LPS stimulated HUVECs was also reduced, as was pro-inflammatory cytokine expression by HUVECs in vitro. It is likely that the effects of DPP4 inhibitors in modifying endothelial cell mediated innate immunity are via a combination of glucose dependent and independent mechanisms. Additional studies are required to determine not only the molecular pathways involved, but also how different DPP4 inhibitors exhibit different modes of action.

3.2. Neutrophils

Neutrophils are highly specialized anti-microbial immune cells and are the first responders to invading pathogens [46]. Neutrophils employ an array of cellular and non-cellular mechanisms to destroy invading pathogens that include phagocytosis and the secretion of potent antimicrobials, proteases, and oxidative species [47,48]. Additionally, neutrophils have a key role in driving the secondary immune response, recruiting and activating macrophages, dendritic cells and lymphocytes, to the site of inflammation via secretion of various cytokines and peroxidases [49]. Pre-clinical and in vitro studies have suggested that DPP4 inhibitors can modulate specific aspects of neutrophil recruitment and activity.

Normal wound healing is characterised by an integrated cascade of events, with neutrophil recruitment and activation a key component to prevent infection by pathogenic organisms [50]. Patients with diabetes have impaired leucocyte function, which can lead to impaired neutrophil migration to the wound [51]. However, in chronic, non-healing wounds, such as those seen in diabetics, persistence of neutrophils at the wound site can exacerbate tissue damage via release of reactive oxygen species, anti-microbial peptides and proteases [52]. In a prospective, randomised open label trial, Marfella et al investigated the effects of Vildagliptin on wound healing in diabetic chronic ulcers. Treatment with Vildagliptin for three months significantly reduced overall wound area, wound related complications and improved wound closure rates, compared to patients on conventional therapies [53]. The authors reported increased expression of vascular endothelial growth factor and increased angiogenesis in the Vildagliptin group [53]. Although leukocyte infiltration was not specifically quantified, a decrease in nitrotyrosine, which is associated with activated neutrophils, was reported in Vildagliptin treated patients. In a murine model of diabetic wound healing, Schurmann et al reported reduced numbers of infiltrating neutrophils to the wound in mice treated with Linagliptin [54], with the authors suggesting an indirect effect of Linagliptin on neutrophil recruitment via COX-2 and MIP-2 [54]. This pre-clinical data supports the observations seen in humans, and suggests DPP4 inhibition may be protective via a possible COX-2 and MIP-2 mediated mechanism.

The effects of a panel of five DPP4 inhibitors on neutrophil functions has been investigated in human neutrophils in vitro. Linagliptin dose-dependently (1 μM to 100 μM) reduced ROS production in LPS-stimulated neutrophils; however, the DPP4 inhibitors, Sitagliptin, Vildagliptin, Alogliptin and Saxagliptin, had little effect on in vitro ROS production.
### Table 2
Candidate DPP4 substrates with identified roles in innate immune responses.

| Substrate                          | N-terminal sequence | Reported Roles in Innate Immunity | Biological Activity | Effect of DPP4 Cleavage |
|-----------------------------------|---------------------|-----------------------------------|---------------------|-------------------------|
| Eotaxin (CCL11)                   | Gly-Pro-Ala         | Eosinophil and basophil migration | Reduced             | Inactivation            |
| Erythropoietin                    | Ala-Pro-Pro         | Inhibits production of macrophage derived inflammatory cytokines; enhances macrophage phagocytic activity | Inactivation        | Reduced                 |
| Gastrin-releasing peptide (GRP)   | Val-Pro-Val         | Induces neutrophil migration       | Inactivation        | Reduced                 |
| Glucagon like peptide 1 (GLP-1)   | His-Ala-Glu         | Induces macrophage polarization    | Inactivation        | Reduced                 |
| Granulocyte-Colony Stimulating Factor (G-CSF) | Gln-Ala-Thr         | Stimulates neutrophil proliferation & differentiation | Inactivation        | Reduced                 |
| Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) | Ala-Pro-Ala         | Recruitment of neutrophils & monocytes; stimulates macrophage activity | Inactivation        | Reduced                 |
| HMGB1                             | Gly-Lys-Gly         | Stimulates expression of cell adhesion molecules; upregulates pro-inflammatory cytokine production | Inactivation        | Reduced                 |
| IP10 (CCL10)                      | Val-Pro-Leu         | Chemotactic for monocytes/macrophages & NK cells; stimulates NK cell degranulation | Reduced             | Altered specificity     |
| ITAC (CCL11)                      | Phe-Pro-Ala         | Chemotactic for monocytes/macrophages & NK cells | Reduced             | Altered specificity     |
| IL-3                              | Ala-Pro-Met         | Monocyte activation & differentiation | Reduced             | Altered specificity     |
| Macrophage-derived chemokine (MDC, CCL22) | Gly-Pro-Tyr         | Recruitment of dendritic cells, NK & Th2 cells | Reduced             | Altered specificity     |
| Monokine induced by IFN-γ (Mig, CCL9) | Tyr-Pro-Val        | Recruitment of T-cells, Reduced | Inactivation        | Reduced                 |
| Neuropeptide-Y (NPY)              | Tyr-Pro-Ser         | Stimulates secretion of pro-inflammatory cytokines by macrophages; stimulates phagocytic activity | Inactivation        | Reduced                 |
| RANTES (CCL5)                     | Ser-Pro-Tyr         | Recruitment of macrophages and NK cells | Reduced             | Inactivation            |
| Stromal-cell derived factor (SDF-1, CCL12) | Lys-Pro-Val        | Monocyte chemotactic Reduced | Reduced             | Altered specificity     |
| Putative adenylyl-cyclase-activating polypeptide (PACAP) | His-Ser-Asp       | Inhibit macrophage chemotaxis, phagocytosis & ROS production; inhibits pro-inflammatory cytokine production by macrophages | Reduced             | Inactivation            |
| Substance P                       | Arg-Pro-Lys         | Stimulate neutrophil & macrophage phagocytic activity; stimulates pro-inflammatory cytokine production by macrophages | Inactivation        | Reduced                 |
| Vasoactive Intestinal Peptide (VIP) | His-Ser-Asp        | Inhibit macrophage chemotaxis, phagocytosis & ROS production; inhibits pro-inflammatory cytokine production by macrophages | Inactivation        | Reduced                 |

Production from human neutrophils [44]. Linagliptin also reduced the adhesion of LPS-activated human neutrophils to an endothelial monolayer in vitro [44]. Unlike other DPP4 inhibitors, Linagliptin is a xanthine analogue and Kroller-Schon and colleagues have suggested potential off-target effects as a result of interactions with xanthine oxidase, an enzyme involved in the production of ROS and nitrogen species [55]; however, activity from xanthine oxidase was not specifically measured. DPP4 inhibition has also been found to modify aspects of neutrophil activity in a mouse model of ischemia–reperfusion injury induced lung graft failure [56]. Treatment of lung-allografts with the irreversible DPP4 inhibitor, AB192 (bis-(4-acetamido phenyl) 1-(s)-prolylpyrrolidine-2(r,s)-phosphonate), prior to surgical transplant improved graft ultrastructure and reduced graft neutrophil infiltration, as determined by markers Ly-6-G and myeloperoxidase activity, compared to untreated controls [56]. The authors also reported that DPP4 inhibitor treatment was associated with increased expression of vasoactive intestinal peptide (VIP) in lung grafts. VIP has been previously been shown to suppress neutrophil infiltration, suggesting a possible indirect mechanism of DPP4 inhibition on neutrophil activity. Our group has previously reported that the DPP4 inhibitors, Ile-Pyr-1(r,s)-TFA and Ile-Thia were associated with lowered colonic myeloperoxidase activity in mice with dextran sulfate sodium induced colitis [57]. Whilst the current evidence suggests that DPP4 inhibitors can modify neutrophil responses in experimental models of inflammation, the specific mechanisms and clinical relevance to humans are yet to be elucidated.

Enzymatically active DPP4 may also act as a neutrophil chemo-repellent. Using an in vitro chemotaxis model, unstimulated and TNF-α stimulated human derived peripheral blood neutrophils were found to migrate away from recombinant DPP4 in a dose dependant manner [58]. When the non-selective DPP4 inhibitors Diprotin A and DPP1 1c hydrochloride were added in combination with the recombinant DPP4 gradient, the chemo-repulsive activity of DPP4 was significantly attenuated suggesting that the ability of DPP4 to act as a chemo-repellent is dependent on its enzymatic activity [58]. The authors also demonstrated that treating mice with aerosolized recombinant DPP4 reduced neutrophil infiltration to the lungs induced by bleomycin, although no changes to other inflammatory cell types were observed [58]. In a separate study of collagen-induced-arthritis, injection of recombinant DPP4 to the joint reduced neutrophil and macrophage infiltration, improving joint inflammation and disease severity [59]; however, DPP4 inhibitors were not used in this study. Whilst these findings could have implications for the long-term use of DPP4 inhibitors on neutrophil recruitment, the absence of data using more highly selective, clinically relevant DPP4 inhibitors mean this effect cannot be clearly delineated.

The collective evidence suggests that DPP4 inhibitors may modify neutrophil recruitment and activity; however, the specific mechanisms involved are still unclear. It is likely that DPP4 inhibitors have both direct and indirect effects on neutrophil functions during specific inflammatory conditions. Additional studies should seek to investigate whether long-term DPP4 inhibitor therapy affects innate immune responses in patients that have become septic or are exposed to infectious pathogens. Furthermore, the precise mechanisms of DPP4 inhibitors in modifying neutrophil functions should be deciphered to determine any possible therapeutic application.

### 3.3. Monocytes and Macrophages

DPP4 activity and expression has been characterised in monocytes, macrophages [60] and in subpopulations of dendritic cells [61–63]. Atherosclerosis is a complex, inflammatory disorder in which macrophages are directly involved in disease pathogenesis [64]. In diabetic apolipoprotein E deficient (ApoE–) mouse models of atherosclerosis, treatment with either Sitagliptin, Anagliptin or a Vildagliptin analogue has been associated with fewer atherosclerotic lesions compared with respective controls [65–67]. Macrophage content and infiltration into the plaques was also reduced in animals treated with a DPP4 inhibitor.
Reduced expression of the pro-inflammatory cytokines TNF-α [65], IL-6 and monocyte chemoattractant protein 1, as well as serum adhesion molecules, VCAM-1 and P-selectin [66], have been identified in the vascular tissue, suggesting that DPP4 inhibitors may cause changes to circulating and locally expressed inflammatory mediators that could modify monocyte and macrophage recruitment and infiltration. Dai et al reported that Sitagliptin in vitro prevented the formation of foam cells, a key component of atherosclerotic plaques, when exposed to oxidized low-density lipoprotein [69]. Sitagliptin also reduced the expression of scavenger receptors including CD36 and LOX-1 in THP-1 cells and CD68 in human monocytes, which are involved in the internalization of oxidized low-density lipoprotein [69].

Shah et al determined the effects of Alogliptin on adipose tissue inflammation in mice deficient for the low-density lipoprotein receptor (LDLR−/−) and fed a high fat diet to induce obesity [70]. Alogliptin treatment for 12 weeks led to reduced numbers of macrophages within adipose tissue, as detected by immunohistochemistry [70]. Alogliptin treatment was associated with reduced numbers of pro-inflammatory M1 macrophages (CD11b+Ly6Chigh) in adipose tissue, and increased gene expression of M2 macrophage markers, CD163 and Ym-1 [70]. The authors also reported that Alogliptin treatment was associated with reduced gene expression of monocyte derived pro-inflammatory cytokines. Using the monocyctic cell line, THP-1, monocyte migration was also found to be reduced in vitro following treatment with either Alogliptin or Sitagliptin. Follow-up studies by Shah et al in an ApoE−/− mouse model of atherosclerosis found monocyte migration to the aortic plaque was reduced in vivo by Sitagliptin [70].

A role for soluble DPP4 protein in stimulating inflammatory responses in macrophages has also been proposed. Ikeda et al found that the addition of enzymatically active, soluble DPP4, dose dependently increased the gene and protein expression of TNF-α in lipopolysaccharide stimulated THP-1 cells and freshly isolated monocytes [71]. The authors also reported that soluble DPP4 mediated increased production of signal transduction proteins that include NF-κB, ERK and c-FOS [71]. Interestingly, treatment with Sitagliptin (1 μM) ameliorated these effects, suggesting that the observed effects were dependent on DPP4 enzyme activity [71]. Lee et al also reported that addition of exogenous recombinant DPP4 to a lipopolysaccharide stimulated macrophage cell line, RAW264.7, in vitro enhanced the expression of TLR4, TLR2, iNOS and cytokines, IL-6, IL-1β and TNF-α [72]. The authors found that Vilaglitacin (0.01 μM–10 μM) treatment reduced iNOS expression, JNK phosphorylation and NF-κB activation, as well as suppressing the increase in production of the cytokines TNF-α, IL-6, and IL-12 p40 [72].

DPP4 inhibitor selectivity has been an important consideration in gliptin drug design to mitigate off-target effects from other DPP family members. Matheussen et al reported high DPP8/9 immunostaining of DPP8 and DPP9 in the macrophage rich regions of human atherosclerotic plaques [60]. DPP8/9 enzyme activity was also high in the cell lystate of the human monocyte cell line, U937 and in monocyte differentiated macrophages [60]. The authors also reported increased DPP8/9 activity in vitro in PMA stimulated U937 cells and monocyte differentiated macrophages. Treatment of lipopolysaccharide or IFN-γ stimulated M1 macrophages with the DPP8/9 inhibitor, 1G244, reduced production of pro-inflammatory cytokines, IL-6, IL-1β and TNF-α [60]. DPP9 silencing using siRNA suggested that the immuno-regulatory effects could be attributable to DPP9 [60]. Macrophage activation was also investigated by Waumann et al in murine bone marrow derived macrophages. Treatment with a DPP8/9 inhibitor reduced TNF-α and IL-6 secretion from macrophages, indicating reduced cell activation [75]. This suggests that at least some effects of DPP inhibition could be due to DPP9.

Although not yet clearly defined, DPP4 and DPP8/9 appear to have specific roles in regulating monocyte and macrophage function and activity. Further studies are necessary to better understand the specific mechanisms of DPPs and whether their roles are confined to specific subpopulations of monocytes and macrophages. Understanding the clinical relevance of DPP4 inhibition in monocyte-macrophage functions may also support the repurposing of FDA approved DPP4 inhibitors as pharmacological targets for the management of chronic inflammatory disorders like atherosclerosis.

4. DPP4 inhibitors and COVID-19

It is prudent to discuss the findings of this review in the context of current global coronavirus disease-19 (COVID-19) pandemic. DPP4/CD26 is the receptor for the Middle East Respiratory Syndrome-Corona Virus (MERS-CoV) [74], binding the amino terminal receptor-binding spike domain S1. The emergence of the novel SARS-CoV-2 virus in Wuhan, China in late 2019 initiated global discussions about whether DPP4/CD26 represented a therapeutic target for COVID-19 as a potential receptor for the SARS-CoV-2 spike protein [75,76]. However, the identification of angiotensin converting enzyme-2 (ACE-2) as the main receptor for virus entry [77,78] and the inability for DPP4 to bind SARS-CoV-2 [79] suggest that DPP4 inhibitors would have little effect in preventing virus pathogenicity. Whilst the role of the innate immune system in COVID-19 is still being unravelled, it is becoming clear that elements of innate immunity are dysregulated during COVID-19 and may play a role in the development of the cytokine storm [80]. The immunomodulatory effects of DPP4 inhibitors discussed in this review suggest a therapeutic benefit that could be investigated in COVID-19 patients. Type-2 diabetes has been associated with poor prognosis in patients with COVID-19 [81]. To date, only one study has reported data on DPP4 inhibitor use in COVID-19 patients, with no advantage reported in patients on a DPP4 inhibitor [82] (primary endpoint: tracheal intubation and/or death within 7 days of admission). With millions of type-2 diabetics already prescribed DPP4 inhibitors globally, it will be interesting to determine outcomes in this patient cohort to glean any clues of therapeutic benefit or otherwise for DPP4 inhibitors.

5. Summary

DPP4 inhibitors have emerged as safe and effective therapeutic options for the management of hyperglycaemia in type-2 diabetes. Whilst early work with non-selective DPP4 inhibitors suggested broad roles for DPP4 in immunity, the emergence of highly selective DPP inhibitors has revealed roles for this enzyme family in specific immune responses (Table 3).

Although a clear mechanism for the immunomodulatory actions of DPP4 inhibitors in innate immunity has not yet been clearly described, the broad repertoire of candidate DPP4 substrates, including chemoattractants, cytokines and neuropeptides indicates possible avenues for investigation (Fig. 2). DPP4 has been referred to as a ‘moonlighting protein’, with cell type dependent physiological actions via either its enzymatic activity or its co-stimulatory activity through its binding partners [10,84]. The findings that different DPP4 inhibitors can have differential effects on immune cell activation and function suggest effects that could be independent of DPP4 enzyme activity. Studies that have reported on the binding properties of different DPP4 inhibitors found evidence of conformational change in the DPP4 protein [85–87]. Whether this could explain the disparate effects of the DPP4 inhibitors remains to be seen; however, additional studies are required to dissect this phenomenon.

The accumulating in vitro and in vivo evidence points to a direct effect of DPP4 inhibitors on innate immunity. However, these effects appear to be multi-factorial, and the glycaemic actions of DPP4 inhibition via GLP-1 could also in part explain the anti-inflammatory actions of DPP4 inhibitors. The chemorepellent properties of the DPP4 protein, as well as the capacity for soluble DPP4 to stimulate inflammatory pathways implies a complex regulatory role for DPP4 in immune cell activation. Observations that these effects could be reversed by DPP4 inhibitors lends further support to the hypothesis that conformational changes induced by DPP4 inhibitors could affect biological activity.
The anti-inflammatory actions of DPP4 inhibitors reported in clinical and pre-clinical studies of endothelial dysfunction, atherosclerosis and diabetic ulcers suggest an additional utility for this drug class. The COVID-19 pandemic has seen a global effort to identify novel pharmaceuticals that could combat this disease. The reported effects of DPP4 inhibitors on suppressing innate immune responses suggests possible applications for COVID-19 and other respiratory infections that could be further investigated. To conclude, the proliferation of DPP4 inhibitors for type-2 diabetes is indicative of their therapeutic benefit and general safety profile. The immunomodulatory effects of DPP4 inhibitors on innate immunity suggest they have further potential clinical applications; however, the precise mechanisms of these inhibitors must be determined to ensure optimum and targeted effects.

CRediT authorship contribution statement

R. Yazbeck: Conceptualization, Investigation, Resources, Writing - original draft, Writing - review & editing, Visualization, Supervision. S. E. Jaenisch: Investigation, Writing - original draft, Writing - review & editing. C.A. Abbott: Conceptualization, Writing - review & editing, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References

[1] M.L. Sulda, C.A. Abbott, P.J. Macrdl, R.K. Hall, B.J. Buson and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia, Cancer Biol. Ther. 10 (2) (2010) 180–189.

[2] R. Yaback, G.S. Howarth, C.A. Abbott, Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30 (11) (2009) 600–607.

[3] R. Yaback, G.S. Howarth, R.N. Butler, M.S. Geier, C.A. Abbott, Biochemical and molecular mechanisms in T cell function, Trends Immunol. 29 (6) (2008) 295–303.

[4] R. Yazbeck, G.S. Howarth, C.A. Abbott, Biochemical and pharmacodynamic determinants of potency and in vivo efficacy and safety, J. Med. Chem. 51 (19) (2008) 6005–6013.

[5] R. Yazbeck, G.S. Howarth, C.A. Abbott, Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30 (11) (2009) 6005–6013.

[6] S. Chen, J. Wu, H. Maw, Y. Zhou, Y. Li, Z. Jin, J.L. Sudmeier, J.H. Lai, W. Wu, S. Grabbe, T. Klein, T. Munzel, A. Daiber, Glucose-independent improvement of endothelial dysfunction in chronic inflammatory disease and uncontrolled diabetes, Circ. J. 77 (5) (2013) 1155–1166.

[7] J. Marcinkeviciene, L. Hamann, M.S. Kirby, Potency, selectivity and prolonged activity of a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, Bioorg. Med. Chem. 20 (1) (2012) 3055–3065.

[8] S. Chen, J. Zhao, W. Li, J. Wang, Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis, Medicine (Baltimore) 96(48) (2017) e952–e959.

[9] B.D. Williams-Herman, E. Round, A.S. Swern, B. Musser, M.J. Davies, P.P. Stein, K. McKeage, Trelagliptin: First Global Approval, Drugs 75 (10) (2015) 1161–1168.

[10] R. Garg, W. Chen, M. Pendergrass, Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational study claims analysis, Diabetes Care 33 (11) (2010) 2349–2354.

[11] A. Connemann, S.E. Brown, P.M. Engeland, H.J. Woerle, E. Pfirr, A. Keller, M. Matteus, D. Baanstra, T. Meinicke, J.T. George, M. von Eynatten, D.K. McGuire, N. Marx, F.T.C. Investigators, Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial, JAMA 322 (12) (2019) 1155–1166.

[12] J. NORMAN, The role of cytokines in the pathogenesis of acute pancreatitis, Am. J. Surg. 175 (1) (1998) 76–83.

[13] A. Bhatnagar, Inflammation in acute and chronic pancreatitis, Curr. Opin. Gastroenterol. 31 (5) (2015) 395–399.

[14] N.M. HANSEN, K.A. Jandeit-Lehmann, Dipeptidyl peptidase IV inhibitors and cardiovascular renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? Diab. Vasc. Dis. Res. 16 (4) (2019) 303–309.

[15] R. Yazbeck, G.S. Howarth, C.A. Abbott, Dipeptidyl peptidase IV inhibition in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor, BMC Pharmacol. 12 (2012).

[16] L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayon, F. Himmelsbach, M. Mark, (R)-Amino-(3-oxo-carboxyl)-5-(2,4,5-trifluorophenyl)-2-methyl-pyrazolo[1,5-d]pyrimidine-2-carboxylic acid (Vildagliptin) and analogues, J. Med. Chem. 51 (19) (2008) 6492–6501.

[17] A. Wang, C. Dorso, L. Lopcho, G. Locke, R. Langish, E. Harstad, P. Shipkova, J. Marcinkiewicz, L. Hamann, M.S. Kirby, Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor, BMC Pharmacol. 12 (2012).

[18] A. WANG, C. Dorso, E. K. Lopcho, G. Locke, R. Langish, E. Harstad, P. Shipkova, J. Marcinkiewicz, L. Hamann, M.S. Kirby, Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor, BMC Pharmacol. 12 (2012).

[19] L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayon, F. Himmelsbach, M. Mark, (R)-Amino-(3-oxo-carboxyl)-5-(2,4,5-trifluorophenyl)-2-methyl-pyrazolo[1,5-d]pyrimidine-2-carboxylic acid (Vildagliptin) and analogues, J. Med. Chem. 51 (19) (2008) 6492–6501.
Inflammation and neutrophils: Cinderella of innate immune system, Int. Immunol. 11 (7) (2012) 721.

6468–6477.

6549–6552.

6380–6381.

6382–6383.

6384–6385.

6386–6387.

6388–6389.

6390–6391.

6392–6393.

6394–6395.

6396–6397.

6398–6399.

6400–6401.

6402–6403.

6404–6405.

6406–6407.

6408–6409.

6410–6411.

6412–6413.

6414–6415.

6416–6417.

6418–6419.

6420–6421.

6422–6423.

6424–6425.

6426–6427.

6428–6429.

6430–6431.

6432–6433.

6434–6435.

6436–6437.

6438–6439.

6440–6441.

6442–6443.

6444–6445.

6446–6447.

6448–6449.

6450–6451.

6452–6453.

6454–6455.

6456–6457.

6458–6459.

6460–6461.

6462–6463.

6464–6465.

6466–6467.

6468–6469.

6470–6471.

6472–6473.

6474–6475.

6476–6477.

6478–6479.

6480–6481.

6482–6483.

6484–6485.

6486–6487.

6488–6489.

6490–6491.

6492–6493.

6494–6495.

6496–6497.

6498–6499.

6500–6501.

6502–6503.

6504–6505.

6506–6507.

6508–6509.

6510–6511.

6512–6513.

6514–6515.

6516–6517.

6518–6519.

6520–6521.

6522–6523.

6524–6525.

6526–6527.

6528–6529.

6530–6531.

6532–6533.

6534–6535.

6536–6537.

6538–6539.

6540–6541.

6542–6543.

6544–6545.

6546–6547.

6548–6549.

6550–6551.

6552–6553.

6554–6555.

6556–6557.

6558–6559.

6560–6561.

6562–6563.

6564–6565.

6566–6567.

6568–6569.

6570–6571.

6572–6573.

6574–6575.

6576–6577.

6578–6579.

6580–6581.

6582–6583.

6584–6585.

6586–6587.

6588–6589.

6590–6591.

6592–6593.

6594–6595.

6596–6597.

6598–6599.

6600–6601.

6602–6603.

6604–6605.

6606–6607.

6608–6609.

6610–6611.

6612–6613.

6614–6615.

6616–6617.

6618–6619.

6620–6621.

6622–6623.

6624–6625.

6626–6627.

6628–6629.

6630–6631.

6632–6633.

6634–6635.

6636–6637.

6638–6639.

6640–6641.

6642–6643.

6644–6645.

6646–6647.

6648–6649.

6650–6651.

6652–6653.

6654–6655.